VivoSense recently published an American Society of Clinical Oncology’s JCO Clinical Cancer Informatics review article, Measuring What Is Meaningful in Cancer Cachexia Clinical Trials: A Path Forward With Digital Measures of Real-World Physical Behavior.
Cancer Cachexia Clinical Trials Metrics
Cancer cachexia is a severe muscle-wasting syndrome that impacts over 80% of advanced cancer patients. Despite well-documented burdens in patients’ physical functioning, effective drug development remains elusive.
This narrative review summarizes existing methods for assessing physical functioning in cancer cachexia. We discuss a path forward with digital health technologies (DHTs) for continuous, comprehensive, and accurate assessments of real-world physical behavior. Recent regulatory developments on using digital measures as clinical outcome assessments in drug development are also highlighted.
Overall, we emphasize the importance of measures that matter to patients. This involves outcomes derived from concepts meaningful to patients, aiding in developing effective treatments for cancer cachexia.
Suvekshya Aryal, MPH; Shelby L. Bachman, PhD; Kaye Lyden, PhD; and Ieuan Clay, PhD